{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:58Z","timestamp":1793924518407,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T00:00:00Z","timestamp":1429833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jpsychores.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychosomatic Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jpsychores.2015.04.008","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T15:09:40Z","timestamp":1429974580000},"page":"175-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Tumour necrosis factor-\u03b1 inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety"],"prefix":"10.1016","volume":"79","author":[{"given":"Rebecca","family":"Abbott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Whear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bethel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Thompson","family":"Coon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dickens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychores.2015.04.008_bb0005","series-title":"Depression in adults with a chronic physical health problem: treatment and management","author":"National Institute for Health and Clinical Excellence","year":"2009"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0010","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.2337\/diacare.28.11.2668","article-title":"The association of comorbid depression with mortality in patients with type 2 diabetes","volume":"28","author":"Katon","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0015","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1093\/eurheartj\/ehl338","article-title":"Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies","volume":"27","author":"Nicholson","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jpsychores.2009.11.006","article-title":"Depression and increased risk of death in adults with stroke","volume":"68","author":"Ellis","year":"2010","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/01.psy.0000146294.82810.9c","article-title":"Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis","volume":"66","author":"van Melle","year":"2004","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00006842-200107000-00015","article-title":"Association of depression and diabetes complications: a meta-analysis","volume":"63","author":"de Groot","year":"2001","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0035","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1192\/bjp.bp.105.018234","article-title":"Contribution of depression and anxiety to impaired health-related quality of life following first myocardial infarction","volume":"189","author":"Dickens","year":"2006","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the World Health Surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pain.2007.05.015","article-title":"Psychosocial predictors of health-related quality of life and health service utilisation in people with chronic low back pain","volume":"135","author":"Keeley","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1176\/appi.psy.43.4.302","article-title":"Depression and anxiety impair health-related quality of life and are associated with increased costs in general medical inpatients","volume":"43","author":"Creed","year":"2002","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/diacare.28.1.59","article-title":"Predictors of health care costs in adults with diabetes","volume":"28","author":"Gilmer","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0060","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1017\/S0033291704001965","article-title":"The risk factors for depression in first myocardial infarction patients","volume":"34","author":"Dickens","year":"2004","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.genhosppsych.2008.04.003","article-title":"Negative illness perceptions are associated with new-onset depression following myocardial infarction","volume":"30","author":"Dickens","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00006842-200201000-00008","article-title":"Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis","volume":"64","author":"Dickens","year":"2002","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S0033291797006478","article-title":"A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII","volume":"28","author":"Prince","year":"1998","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/JGP.0b013e31819c498c","article-title":"A longitudinal community-based study of chronic illness, cognitive and physical function, and depression","volume":"17","author":"Turvey","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0085","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1192\/bjp.165.5.593","article-title":"Predictors of psychiatric morbidity in cancer patients","volume":"165","author":"Harrison","year":"1994","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0090","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0095","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","article-title":"CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies","volume":"150","author":"Valkanova","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eurpsy.2008.03.013","article-title":"Depression, comorbidities and the TNF-alpha system","volume":"23","author":"Himmerich","year":"2008","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpsychires.2014.04.021","article-title":"Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity","volume":"55","author":"Schmidt","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1017\/S0033291708003723","article-title":"Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study","volume":"39","author":"Gimeno","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0120","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.bbi.2009.04.011","article-title":"A prospective evaluation of the directionality of the depression\u2013inflammation relationship","volume":"23","author":"Stewart","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archpsyc.58.5.445","article-title":"Cytokine-associated emotional and cognitive disturbances in humans","volume":"58","author":"Reichenberg","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbi.2004.10.003","article-title":"Acute inflammation and negative mood: mediation by cytokine activation","volume":"19","author":"Wright","year":"2005","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpsychores.2004.03.010","article-title":"Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment","volume":"58","author":"Beratis","year":"2005","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.biopsych.2014.01.008","article-title":"Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial","volume":"76","author":"Su","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.neubiorev.2013.02.004","article-title":"Depression after myocardial infarction: TNF-alpha-induced alterations of the blood-brain barrier and its putative therapeutic implications","volume":"37","author":"Liu","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0155","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jpsychires.2013.01.007","article-title":"Antidepressant effects of TNF-alpha blockade in an animal model of depression","volume":"47","author":"Krugel","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0160","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/npp.2014.199","article-title":"Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge","volume":"40","author":"Camara","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jpsychores.2015.04.008_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","article-title":"Infliximab improves quality of life in patients with Crohn's disease","volume":"8","author":"Lichtenstein","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0170","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2008.102509","article-title":"Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial","volume":"69","author":"Kekow","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0175","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00296-013-2671-x","article-title":"The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation","volume":"33","author":"Arisoy","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00296-010-1616-x","article-title":"Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level","volume":"32","author":"Ertenli","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0185","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1038\/tp.2013.27","article-title":"Anxiety disorders and inflammation in a large adult cohort","volume":"3","author":"Vogelzangs","year":"2013","journal-title":"Transl psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0190","series-title":"Systematic reviews: CRDs guidance for undertaking reviews in healthcare","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0195","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0200","series-title":"Cochrane handbook for systematic reviews of interventions: the cochrane collaboration","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0205","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kes142","article-title":"Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial","volume":"51","author":"van der Heijde","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0215","series-title":"Introduction to meta-analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0220","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archpedi.158.6.595","article-title":"Meta-analysis based on standardized effects is unreliable","volume":"158","author":"Cummings","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0230","series-title":"Statistical power analysis for the behavioural sciences (2nd ed)","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0235","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/rheumatology\/ker377","article-title":"Evaluation of Ankylosing Spondylitis Quality of Life questionnaire: responsiveness of a new patient-reported outcome measure","volume":"51","author":"Packham","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2474-14-13","article-title":"Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis","volume":"14","author":"Bae","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/RHU.0000000000000055","article-title":"Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region","volume":"20","author":"Machado","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0250","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0255","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0260","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0265","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1756-185X.2011.01680.x","article-title":"Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial","volume":"15","author":"Kim","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0275","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1468-3083.2009.03321.x","article-title":"Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54weeks: the CRYSTEL study","volume":"23","author":"Dauden","year":"2009","journal-title":"J. Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0280","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"J. Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0285","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175.x","article-title":"Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. [Erratum appears in Am J Gastroenterol. 2009 Jul;104(7):1894]","volume":"103","author":"Loftus","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0290","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.04.008_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/JCP.0b013e3181dcf0de","article-title":"TNF-antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial","volume":"30","author":"Maas","year":"2010","journal-title":"J Clin Psychopharmacol"}],"container-title":["Journal of Psychosomatic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399915002445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399915002445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T02:22:25Z","timestamp":1537669345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022399915002445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022399915002445"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychores.2015.04.008","relation":{},"ISSN":["0022-3999"],"issn-type":[{"value":"0022-3999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour necrosis factor-\u03b1 inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychosomatic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychores.2015.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}